Dawei Xuan

1.2k total citations
34 papers, 994 citations indexed

About

Dawei Xuan is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Dawei Xuan has authored 34 papers receiving a total of 994 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 12 papers in Epidemiology and 12 papers in Molecular Medicine. Recurrent topics in Dawei Xuan's work include Antibiotics Pharmacokinetics and Efficacy (15 papers), Antibiotic Resistance in Bacteria (12 papers) and Pneumonia and Respiratory Infections (11 papers). Dawei Xuan is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (15 papers), Antibiotic Resistance in Bacteria (12 papers) and Pneumonia and Respiratory Infections (11 papers). Dawei Xuan collaborates with scholars based in United States, Spain and United Kingdom. Dawei Xuan's co-authors include David P. Nicolau, Charles H. Nightingale, Ronald Shazer, Dana J. Nickens, Michael Amantea, Joanna C. Masters, Richard Quintiliani, Pamela R. Tessier, C H Nightingale and Kalpana B. Patel and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Dawei Xuan

33 papers receiving 956 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dawei Xuan United States	17	358	340	307	228	209	34	994
Mallika Lala United States	13	500 1.4×	212 0.6×	113 0.4×	44 0.2×	181 0.9×	25	936
Luning Zhuang United States	17	107 0.3×	278 0.8×	144 0.5×	29 0.1×	239 1.1×	24	643
Selda Aydın Belgium	19	330 0.9×	65 0.2×	65 0.2×	69 0.3×	91 0.4×	69	1.1k
M. R. Halie Netherlands	20	200 0.6×	106 0.3×	154 0.5×	63 0.3×	46 0.2×	77	1.2k
Yifeng Luo China	16	116 0.3×	47 0.1×	94 0.3×	69 0.3×	147 0.7×	33	1.0k
Stuart Oliver United Kingdom	17	268 0.7×	176 0.5×	216 0.7×	20 0.1×	46 0.2×	29	1.1k
Robin Michelet Germany	13	128 0.4×	187 0.6×	94 0.3×	20 0.1×	42 0.2×	65	703
Jennifer L. Hoover United States	14	118 0.3×	247 0.7×	160 0.5×	10 0.0×	289 1.4×	23	883
Thomas J. Gniadek United States	14	125 0.3×	39 0.1×	114 0.4×	38 0.2×	87 0.4×	36	705
Richard Schwameis Austria	16	151 0.4×	97 0.3×	186 0.6×	21 0.1×	65 0.3×	48	669

Countries citing papers authored by Dawei Xuan

Since Specialization

Citations

This map shows the geographic impact of Dawei Xuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dawei Xuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dawei Xuan more than expected).

Fields of papers citing papers by Dawei Xuan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dawei Xuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dawei Xuan. The network helps show where Dawei Xuan may publish in the future.

Co-authorship network of co-authors of Dawei Xuan

This figure shows the co-authorship network connecting the top 25 collaborators of Dawei Xuan. A scholar is included among the top collaborators of Dawei Xuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dawei Xuan. Dawei Xuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brooun, Alexei, et al.. (2025). Abstract 390: ERAS-0015 is a pan-RAS molecular glue with best-in-class potential in RAS mutant solid tumors. Cancer Research. 85(8_Supplement_1). 390–390.

Maitland, Michael L., Jasgit C. Sachdev, Manish Sharma, et al.. (2021). First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clinical Cancer Research. 27(16). 4511–4520. 63 indexed citations

Hong, David S., Lyudmila Bazhenova, Byoung Chul Cho, et al.. (2020). First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET. European Journal of Cancer. 138. S1–S1. 6 indexed citations

Masters, Joanna C., Dana J. Nickens, Dawei Xuan, Ronald Shazer, & Michael Amantea. (2017). Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Investigational New Drugs. 36(1). 121–135. 219 indexed citations

Shapiro, Geoffrey I., Ulka N. Vaishampayan, Patricia LoRusso, et al.. (2017). First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Investigational New Drugs. 35(3). 315–323. 32 indexed citations

Sachdev, Jasgit C., Michael L. Maitland, Monica Sharma, et al.. (2016). A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA). Annals of Oncology. 27. vi570–vi570. 15 indexed citations

Chen, Xiaohong, Nahor Haddish‐Berhane, Paul A. Moore, et al.. (2016). Mechanistic Projection of First‐in‐Human Dose for Bispecific Immunomodulatory P‐Cadherin LP‐DART: An Integrated PK/PD Modeling Approach. Clinical Pharmacology & Therapeutics. 100(3). 232–241. 32 indexed citations

Wołk, Robert, William Smith, Joel M. Neutel, et al.. (2009). Blood Pressure Lowering Effects of a New Long-Acting Inhibitor of Phosphodiesterase 5 in Patients With Mild to Moderate Hypertension. Hypertension. 53(6). 1091–1097. 24 indexed citations

Xuan, Dawei, David P. Nicolau, & Charles H. Nightingale. (2004). Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. International Journal of Antimicrobial Agents. 23(3). 291–294. 39 indexed citations

10.

Li, Chonghua, Dawei Xuan, Ming Ye, Charles H. Nightingale, & David P. Nicolau. (2004). Simultaneous analysis of piperacillin and tazobactam in rabbits: application to pharmacokinetic study. Biomedical Chromatography. 19(1). 99–106. 7 indexed citations

11.

Kim, Myo‐Kyoung, Blair Capitano, Holly M. Mattoes, et al.. (2002). Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin‐Tazobactam. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 22(5). 569–577. 37 indexed citations

12.

Mattoes, Holly M., Blair Capitano, Myo‐Kyoung Kim, et al.. (2002). Comparative Pharmacokinetic and Pharmacodynamic Profile of Piperacillin/Tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy. 48(2). 59–63. 18 indexed citations

13.

Xuan, Dawei, et al.. (2002). Pharmacodynamic Assessment of Ertapenem (MK-0826) against Streptococcus pneumoniae in a Murine Neutropenic Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 46(9). 2990–2995. 37 indexed citations

14.

Kim, Myo‐Kyoung, Wen Zhou, Pamela R. Tessier, et al.. (2002). Bactericidal Effect and Pharmacodynamics of Cethromycin (ABT-773) in a Murine Pneumococcal Pneumonia Model. Antimicrobial Agents and Chemotherapy. 46(10). 3185–3192. 28 indexed citations

15.

Xuan, Dawei, et al.. (2001). Determination of BMS-284756, a new quinolone, in mouse serum by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B Biomedical Sciences and Applications. 765(1). 37–43. 5 indexed citations

16.

Xuan, Dawei, David P. Nicolau, C H Nightingale, & Richard Quintiliani. (2001). Circulating Tumor Necrosis Factor-Alpha Production during the Progression of Rat Endotoxic Sepsis. Chemotherapy. 47(3). 194–202. 6 indexed citations

17.

Xuan, Dawei, Mingkang Zhong, Holly M. Mattoes, et al.. (2001). Streptococcus pneumoniae Response to Repeated Moxifloxacin or Levofloxacin Exposure in a Rabbit Tissue Cage Model. Antimicrobial Agents and Chemotherapy. 45(3). 794–799. 21 indexed citations

18.

Xuan, Dawei. (2000). Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. International Journal of Antimicrobial Agents. 15(3). 185–191. 13 indexed citations

19.

McNabb, JoCarol, Robert C. Owens, Dawei Xuan, et al.. (2000). Comparison of azithromycin leukocyte disposition in healthy volunteers and volunteers with AIDS. International Journal of Antimicrobial Agents. 16(1). 37–43. 6 indexed citations

20.

Nicolau, David P., Charles H. Nightingale, Pamela R. Tessier, et al.. (1995). The Effect of Fleroxacin and Ciprofloxacin on the Pharmacokinetics of Multiple Dose Caffeine. Drugs. 49(Supplement 2). 357–359. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact